icad inc

icad — Merger or Acquisition (April 2025)

23 slides from icad's merger presentation, Apr 17, 2025

  1. Slide 1: Media Roundtable: Accelerating AI-Powered Early Detection and Diagnosis of Breast Cancer

    April 16, 2025 | 12:00 ET Media Roundtable Accelerating AI - Powered Early Detection and Diagnosis of Breast Cancer

  2. Slide 2: No Offer or Solicitation

    No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or s

  3. Slide 3: Forward-Looking Statements

    Forward - Looking Statements This communication contains certain “forward - looking statements” within the meaning of the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act of 193

  4. Slide 4: Speakers

    Kees Wesdorp, PhD President and Chief Executive Officer DeepHealth Greg Sorensen, MD Chief Science Officer RadNet, Inc. Speakers Dana Brown President, CEO, and Chairman of the Board iCAD, Inc. Sham Sokka, PhD Chief Operating and Technology Officer DeepHealth

  5. Slide 5: Agenda

    Agenda 01 RadNet Vision and DeepHealth Mission in Breast Health [10 min] Gregory Sorensen, MD, Chief Science Officer, RadNet, Inc. Kees Wesdorp, PhD, President and CEO, DeepHealth 02 03 Q&A [10 min] iCAD Acquisition Accelerating our Mission [17 min] Kees Wesdorp, PhD, President and CEO, DeepHealth P

  6. Slide 6: RadNet and DeepHealth Vision

    01 RadNet and DeepHealth Vision

  7. Slide 7: RadNet - A national leader in diagnostic imaging services and digital health solutions

    RadNet - A national leader in diagnostic imaging services and digital health solutions Worldwide Leader in Imaging AI State - of - the - art AI tools for breast, lung, and prostate cancer screening Industry Leading IT Solutions Complete viewing, scheduling, patient outreach tracking, image storage,

  8. Slide 8: RadNet already demonstrates leadership in earlier and more accurate breast cancer detection

    • RadNet performs ~1.9M mammograms per year, 4.4% of all mammograms in US , and 50,000+ breast biopsies per year • RadNet’s Enhanced Breast Cancer Detection program – powered by DeepHealth’s SmartMammo AI – enables 21% higher cancer detection rate 1 across all races and ages and lowers recall rates

  9. Slide 9: RadNet already demonstrates leadership in earlier and more accurate breast cancer detection

    • RadNet performs ~1.9M mammograms per year, 4.4% of all mammograms in US , and 50,000+ breast biopsies per year • RadNet’s Enhanced Breast Cancer Detection program – powered by DeepHealth’s SmartMammo AI – enables 21% higher cancer detection rate 1 across all races and ages and lowers recall rates

  10. Slide 10: Empowering breakthroughs in care through imaging - Our mission

    Empowering breakthroughs in care through imaging Our mission

  11. Slide 11: Global leader in AI-powered health informatics

    Global leader in AI - powered health informatics 400+ Customers worldwide* Integrating capabilities Diverse patient data Large data sets enable development, validation, and impact across diverse patient populations Global footprint with local clinical expertise RadNet’s Digital Health segment * Dire

  12. Slide 12: Our unique capabilities

    Our unique capabilities Delivering at scale Vertically integrated Clinically proven 1.3M+ AI - powered diagnoses per year 20M+ Managed imaging studies per year 300+ AI - powered cancer screening sites in the US and Europe Demonstrated clinical impact, e.g., 21% increase in breast cancer detection ra

  13. Slide 13: Empowering 300+ sites globally

    Empowering 300+ sites globally Delivering meaningful impact through AI - powered screening at scale 12 Leading breast cancer screening in the USA 260+ clinical sites Leading lung cancer screening in Europe 50+ clinical sites

  14. Slide 14: iCAD Acquisition Accelerating our Mission

    02 iCAD Acquisition Accelerating our Mission

  15. Slide 15: RadNet has signed a definitive agreement to acquire iCAD

    The acquisition will strengthen RadNet’s DeepHealth leadership in AI - driven Breast Cancer solutions by: • Accelerating scale across commercial, product, and engineering functions to meet growing market demand. • Expanding reach to a combined 10 million annual mammograms, over 1,700 provider sites,

  16. Slide 16: iCAD, a global leader in AI-powered breast health solutions

    Annual Revenue $19.6M FY 24 Their ProFound AI ® Breast Health Suite is a highly accurate, clinically validated, concurrent AI reader designed to assist in early breast cancer detection, density assessment, and short - term risk by analysing mammogram images in real time. 50+ Countries Served 1.5K+ H

  17. Slide 17: Financial Overview

    • 2024 actuals: $19.6M • Following the acquisition expected positive Adjusted EBITDA run rate by end of 2026 2 • 2025 guidance: $80 - 90M 1 • 2025 guidance: $15 - 17M Adjusted EBITDA 1 2 Revenue Earnings 1 Guidance issued as of February 27, 2025, and not being reaffirmed or updated hereby. 2 Adjuste

  18. Slide 18: Acquisition expected to create attractive potential synergies

    Commercial synergies Cost synergies • DeepHealth offerings into iCAD installed base • Access to 50+ countries, European growth acceleration in screening solutions • Shared funnel opportunities • $7M+ run rate cost synergies identified: ~$4M direct savings, e.g., board of directors, public company co

  19. Slide 19: iCAD personnel expected to accelerate DeepHealth's growth plans

    • Strong track record with global reach to develop, market, deploy, and service AI solutions at scale. • Partially fulfilling pre - existing hiring plans of DeepHealth to drive external growth. 26 FTE 26 FTE 14 FTE Product and R&D* Commercial** iCAD workforce, total 66 FTE 1 Support functions * Incl

  20. Slide 20: Most comprehensive Breast AI Portfolio

    Integrated Viewing & Reporting AI - powered Cancer Detection End to End Solution for Screening 1 Previously known as Assure. Safeguard Review Most comprehensive Breast AI Portfolio From AI only to complete technology stack for screening Value Clinical Impact Workflow Efficiency Revenue Generation Pr

  21. Slide 21: Portfolio of solutions

    Portfolio of solutions Improving operational efficiency, clinical excellence, and the delivery of care Lung Profound & SmartMammo TM Prostate Brain Operations Suite TM Diagnostic Suite TM Tech Live TM RIS/PACS Enterprise Imaging Population Health

  22. Slide 22: Q&A

    Q&A

  23. Slide 23: DeepHealth

    deephealth

Icad — Merger or Acquisition (April 2025) on 6ix